Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Treatment Updates in Chronic Lymphocytic Leukemia

EP. 1: TP53 and Deletion 17p as Prognostic Factors in CLL

March 31st 2018

EP. 2: Other Prognostic Factors in Chronic Lymphocytic Leukemia

March 31st 2018

EP. 3: Impact of Prognostic Factors on Clinical Decisions in CLL

March 31st 2018

EP. 4: Evolution of Biological Understandings in CLL

March 31st 2018

EP. 5: Selecting the Optimal Frontline Therapy in CLL

March 31st 2018

EP. 6: Sequencing Strategies in Frontline CLL

March 31st 2018

EP. 7: Ibrutinib's Value as Frontline Therapy in CLL

March 31st 2018

EP. 8: Novel Frontline Combinations With Ibrutinib in CLL

March 31st 2018

EP. 9: Approaching Therapy for Relapsed/Refractory CLL

March 31st 2018

EP. 10: CLL: Post-Ibrutinib or Chemoimmunotherapy Approaches

March 31st 2018

EP. 11: Evaluating Pharmacologic Agents in Relapsed/Refractory CLL

March 31st 2018

EP. 12: Continuing Therapy in Relapsed/Refractory CLL

March 31st 2018

EP. 13: Novel Approaches to Treating Relapsed/Refractory CLL

March 31st 2018

EP. 14: Relapsed/Refractory CLL: Evaluating Other Novel Agents

March 31st 2018

EP. 15: The Evolving Treatment Landscape of CLL

March 31st 2018
Advertisement
Advertisement

Trending on OncLive

1

Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma

2

Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond

3

STRIDE Plus TACE With/Without Lenvatinib Improves Responses in Embolization-Eligible HCC

4

Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC

5

Hematologists Detail Practice-Shaping Data That Emerged at EHA 2026 (VIDEO)

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us